Investigating the effect of Empagliflozin on the weight of prediabetes and diabetic patients: A Quasi-experimental study

This study was conducted as a quasi-experimental intervention on 43 patients with prediabetes or type 2 diabetes aged 18 to 65 who were referred to one of the affiliated clinics of Kerman University of Medical Sciences in 2022 and 2023. Patients with diabetes with an HbA1c level of up to 0.5% higher than the treatment target, provided that they were not using other blood glucose-lowering medications, were enrolled in the study. All these patients received 10 milligrams of empagliflozin once daily for three months, and weight , body mass index, waist circumference, systolic blood pressure, and diastolic blood pressure were evaluated monthly and at the end of the third month.本研究针对2022至2023年转诊至克尔曼医科大学（Kerman University of Medical Sciences）附属诊所之一的43名18~65岁前驱糖尿病（prediabetes）或2型糖尿病（type 2 diabetes）患者开展类实验干预。本研究纳入糖化血红蛋白（HbA1c）水平较治疗目标高出不超过0.5%、且未使用其他降糖药物的糖尿病患者；所有受试者均每日单次口服10毫克恩格列净（empagliflozin），干预时长为三个月，并于每月及干预满三个月末，对受试者体重、体重指数、腰围、收缩压及舒张压进行评估。